Imagine you're a detective looking at a crime scene, but you can only dust for one type of fingerprint at a time. That's how most tissue diagnostics work today — one marker, one test, one round. This project built tiny molecular "barcodes" out of DNA that attach to disease proteins and light up in different colors, so pathologists can spot many disease signals in a single tissue sample at once. They tested these barcodes on skin cancer (melanoma) and a rare genetic muscle disease.
Pathologists and drug researchers currently lack a convenient, high-throughput method for detecting multiple disease biomarkers simultaneously in tissue samples. Each biomarker typically requires a separate staining round, limiting throughput and making comprehensive molecular profiling slow and expensive. This bottleneck delays cancer diagnosis precision and drug efficacy evaluation.
The team built immuno-nanodecoders — self-assembled DNA nanostructures conjugated to antibodies and proteins that detect biomarkers through reversible fluorescence signals. Specific deliverables include DNA-based nanodecoders functioning via hybridization reactions (D1.2), DNA:RNA nanostructures using RNase H enzymatic reactions (D2.2), structural characterization of nanodecoder design constraints (D1.5, D1.6), and molecular characterization of the catalytic mechanism (D2.5, D2.6).
If you are a diagnostics company struggling with the limitation of detecting only a few biomarkers per tissue slide — this project developed self-assembled DNA nanostructures that reversibly change fluorescence output, enabling layer-by-layer detection of essentially unlimited biomarkers in a single tissue sample using standard optical fluorescence microscopy.
If you are a pharma R&D team evaluating experimental therapies and need to measure how multiple biomarkers respond simultaneously — this project created nucleic acid-protein conjugate nanodevices specifically tested to evaluate in vitro response to experimental therapies on melanoma and glycogenosis type II cellular models.
If you are a digital pathology company looking to increase the throughput and depth of biomarker imaging — this project addressed the current lack of a high-throughput, convenient method for in situ quantitative microscopic analysis. The nanodecoders work with standard fluorescence microscopy, meaning potential integration into existing imaging workflows.
No commercial pricing or licensing terms are available. This was a EUR 441,000 MSCA-RISE staff exchange project focused on fundamental research and researcher training across 5 partners. Any commercialization would require significant further development and investment.
Not yet. The project operated entirely in academic and research settings with 0 industrial partners. The 38 deliverables are heavily weighted toward researcher training and molecular characterization rather than manufacturing processes or scale-up. Based on available project data, no pilot production or clinical validation was conducted.
Based on available project data, there is no mention of patents filed or licensing frameworks. The consortium of 3 universities and 2 research organizations across 4 countries (Italy, UK, US, Argentina) would need to clarify IP ownership. Contact the coordinator at Universita degli Studi di Roma Tor Vergata for details.
The project objective states that biomarker imaging currently lacks a high-throughput, convenient method for in situ quantitative microscopic analysis. The nanodecoder approach claims essentially unlimited multiplexing capacity, limited only by the number of distinct nanostructure designs, and works with standard optical fluorescence microscopy.
The nanodecoders were specifically applied to skin cancer (melanoma) and glycogenosis type II cellular models. The project also evaluated in vitro response to experimental therapies on these disease models. The underlying technology is disease-agnostic and could theoretically target any protein biomarker.
The project ran from 2015 to 2019 and focused on fundamental molecular design and characterization. Deliverables describe studying behavior of DNA nanostructures in solution and on surfaces, and training researchers. Based on available project data, a commercial product would likely require several more years of development, validation, and regulatory clearance.
Yes. Any diagnostic device used on patient tissue samples would need to meet IVD (In Vitro Diagnostic) regulations in the EU (IVDR) and FDA clearance in the US. Based on available project data, no regulatory pathway work has been initiated.
This is a purely academic consortium — 3 universities and 2 research organizations across Italy, UK, US, and Argentina, with zero industrial partners and zero SMEs. The MSCA-RISE funding scheme is designed for staff exchanges and training, not product development. The 0% industry ratio means the technology has had no exposure to commercial requirements, manufacturing constraints, or market validation. For a business looking to adopt this, you would be starting from scratch on commercialization with an academic team that has deep molecular biology expertise but no demonstrated interest in or capacity for bringing a product to market.
Universita degli Studi di Roma Tor Vergata, Italy — contact through university research office or SciTransfer can facilitate introduction
Want to explore licensing this multiplexed biomarker detection technology? SciTransfer can connect you with the research team and help assess commercial viability.
